What's happening
This bill requires the Superintendent of Financial Services to refer insulin pricing to the Drug Accountability Board for review and public reporting.
Why it matters
Shines a light on insulin pricing by mandating a formal investigation. , which could reveal whether price increases are "significant and unjustified," potentially pressuring manufacturers and insurers to justify or reconsider their practices.
Directly evaluates the real-world impact for consumers. by assessing how insulin prices affect insurance premiums, overall affordability, and the practical value of the drug—key factors for anyone who depends on insulin or pays for it through insurance.
Takes a fresh look at the state’s insulin cost-sharing cap. to determine if it's actually meeting the needs of consumers, which could lead to policy changes that make insulin more affordable for people who rely on it.
Ensures transparency and public accountability. by requiring the findings to be published online and reported to top state officials, making it harder for stakeholders to ignore or downplay the issue.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Review Insulin Price Hikes
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to rules
- Delivered to senate
- Passed assembly
- Ordered to third reading rules cal.652
- Rules report cal.652
- Reported
- Reported referred to rules
- Reference changed to ways and means
- Referred to insurance
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
10475
IN ASSEMBLY
May 27, 2022
Introduced by COMMITTEE ON RULES -- (at request of M. of A. Niou) -read once and referred to the Committee on Insurance
AN ACT to require the Superintendent of Financial Services to refer the drug insulin to the Drug Accountability Board for examination related to price increases and consumer impacts
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The Superintendent of Financial Services shall refer insulin to the Drug Accountability Board. Such board shall examine all forms of insulin medications pursuant to paragraph (1) of subsection (f) of section 202 of the insurance law and report on its findings, including but not limited to:
(a) the drug's impact on the premium costs for commercial insurance in this state and the drug's affordability and value to the public;
(b) whether increases in the price of the drug over time were significant and unjustified; and
(c) pursuant to part DDD of chapter 56 of the laws of 2020, examine the cap on cost-sharing for insulin related to appropriateness and whether such cap is suitable to meet consumer needs.
§ 2. The Superintendent of Financial Services shall prepare a report based on the findings of the Drug Accountability Board. Within twelve months of the effective date of this act, the Superintendent of Financial Services shall:
(a) publish the report of his or her findings on the department of financial service's website in a location easily accessible to the public; and
(b) deliver a copy of the report to the governor, the temporary president of the senate and the speaker of the assembly.
§ 3. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD15990-01-2
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.